Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to a specific active control regimen used in clinical research, consisting of the quadrivalent meningococcal conjugate vaccine **Menactra** (MCV4) and the tetanus, diphtheria, and acellular pertussis booster vaccine **Adacel** (Tdap), administered concomitantly with a saline injection. This regimen was utilized as a comparator arm in a Phase 2 clinical trial (NCT01461993) sponsored by **Pfizer** to evaluate the safety and immunogenicity of the bivalent rLP2086 meningococcal group B vaccine (**Trumenba**) when given alongside routine adolescent vaccinations. Menactra provides protection against *Neisseria meningitidis* serogroups A, C, Y, and W-135, while Adacel provides booster immunity against tetanus, diphtheria, and pertussis. In this specific study context, the saline injection served as a placebo for the investigational meningococcal group B vaccine component.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Menactra + Adacel + saline.